438
Participants
Start Date
January 15, 2022
Primary Completion Date
January 15, 2024
Study Completion Date
January 15, 2025
Infliximab
Infliximab, 5mg/kg at week 0,2,6 and schedule administration at every 8 weeks
Vedolizumab
Vedolizumab, 300mg at week 0,2,6 and schedule administration at every 8 weeks
Mesalazine
Mesalazine, 4-6g/d, systemic and/or topical administration
RECRUITING
the Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou
NOT_YET_RECRUITING
People's Hospital of Chongqing, Chongqing
RECRUITING
First People's Hospital of Foshan, Guangzhou
RECRUITING
Guangzhou Panyu Central Hospital, Guangzhou
RECRUITING
Nanhai Hospital, Southern Medical University, Guangzhou
RECRUITING
Shunde Hospital of Southern Medical University, Guangzhou
RECRUITING
First Affiliated Hospital of Shantou University Medical College, Shantou
NOT_YET_RECRUITING
The Second Affiliated Hospital of Dalian Medical University, Dalian
RECRUITING
Shengjing Hospital, Shenyang
RECRUITING
General Hospital of Tianjin Medical University, Tianjin
NOT_YET_RECRUITING
Zhejiang University, Hanzhou
Sixth Affiliated Hospital, Sun Yat-sen University
OTHER